GV101 in Healthy Obese Participants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions
Weight Management
Interventions
DRUG

GV101

GV101 suspension

DRUG

GV101 placebo

GV101 placebo suspension

Trial Locations (20)

28304

Coastal Research Institute, LLC, Fayetteville

35976

Lakeview Clinical Research, LLC, Guntersville

40213

Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville

44122

Velocity Clinical Research - Cleveland, Cleveland

58104

Lillestol Research, LLC, Fargo

59701

Mercury Street Medical, Butte

63303

Study Metrix Research, City of Saint Peters

64131

Kansas City Research Institute, Kansas City

70072

Tandem Clinical Research, Marrero

75230

Velocity Clinical Research - Dallas, Dallas

84405

Advanced Research Institute - Ogden, Ogden

84790

Chrysalis Clinical Research, St. George

85712

Arizona Clinical Trials, Tucson

91763

Catalina Research Institute, LLC, Montclair

91978

Encompass Clinical Research, Spring Valley

08009

Hassman Research Institute, Berlin

Unknown

Hadassah Medical Center Ein Karem, Jerusalem

Hasharon Hospital, Petah Tikva

Rabin Medical Center, Beilinson Hospital, Petah Tikva

Sheba Medical Center, Tel Litwinsky

All Listed Sponsors
lead

Graviton Bioscience Corporation

INDUSTRY

NCT06979505 - GV101 in Healthy Obese Participants | Biotech Hunter | Biotech Hunter